Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone infarction15.02.04.031; 24.04.05.0110.000052%-
Mitochondrial cytopathy14.11.02.0080.000052%-
Xanthogranuloma01.13.04.005; 15.09.01.009; 16.21.04.0050.000052%-
Pulmonary cavitation22.01.02.0220.000035%-
Bone marrow oedema01.05.01.019; 15.02.01.0050.000035%-
Small intestinal haemorrhage07.12.03.002; 24.07.02.0190.000087%
Non-alcoholic steatohepatitis09.01.07.035; 14.08.04.0240.000070%-
Insulin-requiring type 2 diabetes mellitus05.06.01.009; 14.06.01.0090.000035%-
Cardiac ventricular thrombosis02.11.01.008; 24.01.05.0060.000070%-
Splenic lesion01.09.02.0170.000035%-
Secondary immunodeficiency10.03.03.0090.000070%-
Intervertebral disc space narrowing15.10.01.0070.000052%-
Necrotising oesophagitis07.04.05.0060.000035%-
Mediastinal haemorrhage22.09.03.008; 24.07.01.0750.000035%
Cubital tunnel syndrome17.09.02.0090.000035%-
Neuroendocrine carcinoma05.08.01.011; 16.24.01.0070.000035%-
Ciliary body disorder06.06.06.0070.000052%-
Aortic dilatation24.03.04.0070.000070%-
Abdominal compartment syndrome07.11.01.017; 24.04.09.0090.000035%-
Thalamus haemorrhage17.08.01.062; 24.07.04.0330.000035%-
Paraneoplastic syndrome16.32.01.0090.000035%-
Cotard's syndrome19.10.01.0030.000052%-
Haemorrhagic ascites07.07.02.003; 09.01.05.007; 24.07.02.0320.000035%-
Choroidal neovascularisation06.10.03.004; 24.03.07.0110.000087%-
Diffuse alveolar damage22.01.01.0190.000035%-
Cerebellar haematoma17.08.01.045; 24.07.04.0220.000035%-
Foot deformity15.10.03.0050.000122%-
Hip deformity15.10.03.0080.000035%-
Pyelocaliectasis20.01.06.0110.000035%-
Leukaemia recurrent01.10.03.005; 16.01.03.0050.000052%-
The 31th Page    First    Pre   31 32 33 34 35    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene